Cancer Treatment: The Critical Factors
Updated: 07/29/2004

References

Agarwal B, Rao CV, Bhendwal S, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology. 1999 Oct;117(4):838-47.

Anon. Ras oncogenes: ras oncogenes in human cancer: a review 1990. Cancer Res. 1990;50(4):1352.

Asamoto M, Ota T, Toriyama-Baba H, et al. Mammary carcinomas induced in human c-Ha-ras proto-oncogene transgenic rats are estrogen-independent, but responsive to d-limonene treatment. Jpn J Cancer Res. 2002 Jan;93(1):32-5.

Bartram CR. Mutations in ras genes in myelocytic leukemias and myelodysplastic syndromes. Blood Cells. 1988;14(2-3):533-8.

Bland J. Farnesyl transferase inhibitors.2001;October 17-21, 2001.

Bonnel RA, Villalba ML, Karwoski CB, et al. Aseptic meningitis associated with rofecoxib. Arch Intern Med. 2002 Mar 25;162(6):713-5.

Brody JE. Aspirin linked to aid in colon cancer fight. New York Times. 1991;141(48, 812):A12.

Cafagna D, Ponte E. [Pulmonary embolism of paraneoplastic origin]. Minerva Med. 1997 Dec;88(12):523-30.

Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001 Jun 15;91(12):2214-21.

Cazzola M. Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin. Med Oncol. 2000 Nov;17 Suppl 1:S11-S16.

Chahinian AP, Propert KJ, Ware JH, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol. 1989 Aug;7(8):993-1002.

Chung JY, Huang C, Meng X, et al. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res. 1999 Sep 15;59(18):4610-7.

Collett ED, Davidson LA, Fan YY, et al. n-6 and n-3 polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes. Am J Physiol Cell Physiol. 2001 May;280(5):C1066-C1075.

Conti F, Vici P. [Vinorelbin in the treatment of breast cancer: current status and prospectives for the future]. Clin Ter. 1998 Jan;149(921):61-74.

Cosgrove RH, Zacharski LR, Racine E, et al. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost. 2002 Feb;28(1):79-87.

De Placido S, Lauria R, Perrone F, et al. Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. Oncology. 2000;58(1):8-14.

Dunst J, Pigorsch S, Hansgen G, et al. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis? Strahlenther Onkol. 1999 Mar;175(3):93-6.

Duursma AM, Agami R. Ras interference as cancer therapy. Semin Cancer Biol. 2003 Aug;13(4):267-73.

Feramisco JR, Clark R, Wong G, et al. Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein. Nature. 1985 Apr 18;314(6012):639-42.

Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol. 1992;313:355-64.

Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992 Apr;3(2):65-71.

Frasci G, D'Aiuto G, Comella P, et al. A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients. Oncology. 2002;62(1):25-32.

Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000;19(1-2):19-27.

Gibbs JB, Kohl NE, Koblan KS, et al. Farnesyltransferase inhibitors and anti-Ras therapy. Breast Cancer Res Treat. 1996;38(1):75-83.

Gralla R, Harper P, Johnson S, et al. Vinorelbine (Navelbine) in the treatment of non-small-cell lung cancer: studies with single-agent therapy and in combination with cisplatin. Ann Oncol. 1999;10 Suppl 5:S41-S45.

Gralla R, Harper P, Johnson S, et al. Vinorelbine (navelbine) in the treatment of non-small-cell lung cancer: recent developments in combination chemotherapy and radiotherapy. Ann Oncol. 1999;10 Suppl 5:S47-S51.

Hanjani P, Nolte S, Shahin MS. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer. Gynecol Oncol. 2002 May;85(2):278-84.

Harper P. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15.

Herrera J, Nava M, Romero F, et al. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis. 2001 Apr;37(4):750-7.

Hohl RJ, Lewis K. Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem. 1995 Jul 21;270(29):17508-12.

Knorr J. Aspirin: the multi-purpose compound not just for headaches anymore. Life Extension Magazine 2000 Feb. 2000;Life Extension Magazine 2000 Feb6(2):50.

Kohli M, Fink LM, Spencer HJ, et al. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis. 2002 Jan;13(1):1-5.

Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer. 1994 Jul 1;74(1):38-45.

Lu X, Xu T, Qian J. [An application value of detecting K-ras and p53 gene mutation in the stool and pure pancreatic juice for diagnosis of early pancreatic cancer]. Zhonghua Yi Xue Za Zhi. 2001 Sep 10;81(17):1050-3.

McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1-6.

Minamoto T, Mai M, Ronai Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review. Cancer Detect Prev. 2000;24(1):1-12.

Moran EM. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol. 2002;21(2):193-201.

Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Expert Rev Anticancer Ther. 2002 Apr;2(2):227-33.

Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001 Aug 22;286(8):954-9.

Nagourney RA. Proceedings of the American Society of Clinical Oncology.1995.

Nagourney RA, Link JS, Blitzer JB, et al. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol. 2000 Jun;18(11):2245-9.

Nakatsugi S, Fukutake M, Takahashi M, et al. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn J Cancer Res. 1997 Dec;88(12):1117-20.

Newmark T. Beyond Aspirin.2000.

NIH/NCI. Angiogenesis Inhibitors in Cancer Research. NIH/NCI Angiogenesis Inhibitors in Cancer Research 1998 Jul 7 Bethesda, MD: National Cancer Institute (Http://Www Slip Net/~Mcdavis/Database/Angio163 Htm).1998;Jul 7

Oliff A. Therapies of the Future: New Molecular Targets for Cancer Therapy.1996

Petrylak DP. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol. 2000 Apr;27(2 Suppl 3):24-9.

Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol. 2002 Aug;20(3 Suppl 1):31-5.

Reddy BS, Rao CV. Colon cancer: a role for cyclo-oxygenase-2-specific nonsteroidal anti-inflammatory drugs. Drugs Aging. 2000 May;16(5):329-34.

Samuels AJBHRSSB. Increased alpha 1 antitrypsin, decreased systemic fibrinolysis, hypercoaguable state and increased fibrin split products in patients with lung cancer. Proc Am Soc Clin Oncol. 1975;(16):238.

Sears B. A Dietary Road Map.1995.

Shammas NW, Moss AJ, Sullebarger JT, et al. Acquired coronary angiogenesis after myocardial infarction. Cardiology. 1993;83(3):212-6.

Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 1999 Oct 6;282(13):1254-7.

Singh A, Purohit A, Hejaz HA, et al. Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate. Mol Cell Endocrinol. 2000 Feb 25;160(1-2):61-6.

Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol. 1994 Apr;21(2 Suppl 3):3-8.

Suh DY. Understanding angiogenesis and its clinical applications. Ann Clin Lab Sci. 2000 Jul;30(3):227-38.

Tew KD, Woodworth A, Stearns ME. Relationship of glutathione depletion and inhibition of glutathione-S-transferase activity to the antimitotic properties of estramustine. Cancer Treat Rep. 1986 Jun;70(6):715-20.

Tew KD, Stearns ME. Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine. Urol Res. 1987;15(3):155-60.

Tew KD, Glusker JP, Hartley-Asp B, et al. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacol Ther. 1992 Dec;56(3):323-39.

Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998 May 29;93(5):705-16.

Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999 Mar 1;59(5):987-90.

Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res. 2000 Jan;6(1):135-8.

Vachtenheim J. Occurrence of ras mutations in human lung cancer. Minireview. Neoplasma. 1997;44(3):145-9.

Vaziri ND, Oveisi F, Reyes GA, et al. Dysregulation of melatonin metabolism in chronic renal insufficiency: role of erythropoietin-deficiency anemia. Kidney Int. 1996 Aug;50(2):653-6.

von Tempelhoff GF, Harenberg J, Niemann F, et al. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. Int J Oncol. 2000 Apr;16(4):815-24.

Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology. 2000 Sep;59(3):245-54.

Weisenthal LM, Kern DH. Prediction of drug resistance in cancer chemotherapy: the Kern and DiSC assays. Oncology (Huntingt). 1991 Sep;5(9):93-103.

Wellness Directory of Minnesota.2002

Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer. 1984 May 15;53(10):2046-52.

Zacharski LR. Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants. Onkologie. 1987 Aug;10(4):264-70.

Zacharski LR, Memoli VA, Rousseau SM, et al. Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung. Cancer. 1987 Dec 1;60(11):2675-81.

Zurborn KH, Bernsmeier R, Schamerowski F, et al. [Coagulation disorders in tumors and hemoblastoses]. Onkologie. 1982 Aug;5(4):186-90.